Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299 is registered in ClinicalTrials.gov with Aimmune Therapeutics, Inc. as lead sponsor.

NCT NCT04056299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04056299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Lead sponsor
Aimmune Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 20, 2019
Completion date
December 28, 2020
Enrollment
15 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hen egg allergy